NASDAQ:GERN - Geron Stock Price, Price Target & More

Geron trades on the NASDAQ under the ticker symbol "GERN."

Geron Co. (NASDAQ:GERN) released its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The biopharmaceutical company earned $0.32 million during the quarter. Geron had a negative return on equity of 26.20% and a negative net margin of 3,300.12%. During the same period in the previous year, the business posted ($0.05) earnings per share. View Geron's Earnings History.

Geron is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Geron.

5 equities research analysts have issued 1 year price objectives for Geron's stock. Their forecasts range from $4.00 to $7.00. On average, they anticipate Geron's share price to reach $5.5833 in the next twelve months. This suggests a possible upside of 62.3% from the stock's current price. View Analyst Ratings for Geron.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Geron saw a increase in short interest in June. As of June 29th, there was short interest totalling 52,712,240 shares, an increase of 18.2% from the June 15th total of 44,580,747 shares. Based on an average daily trading volume, of 4,769,004 shares, the short-interest ratio is presently 11.1 days. Approximately 30.6% of the company's shares are sold short. View Geron's Current Options Chain.

Some companies that are related to Geron include Endo International (ENDP), TESARO (TSRO), Spectrum Pharmaceuticals (SPPI), Akcea Therapeutics (AKCA), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Myokardia (MYOK), Prestige Brands (PBH) and Phibro Animal Health (PAHC).

Media stories about GERN stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Geron earned a media sentiment score of 0.20 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.60 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of GERN stock can currently be purchased for approximately $3.44.

Geron has a market capitalization of $626.55 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]